Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03498131 · ClinicalTrials.gov registry record · Early Phase 1
Melatonin in Patients With Multiple Sclerosis (MS).
A Early Phase 1 study of Relapsing Remitting Multiple Sclerosis, sponsored by Providence Health & Services.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT03498131 is a Early Phase 1 study of Relapsing Remitting Multiple Sclerosis that has completed, run by Providence Health & Services. The registered enrollment target is 30 participants, below the 201-participant average among 25 other Relapsing Remitting Multiple Sclerosis trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03498131, a Early Phase 1 study of Relapsing Remitting Multiple Sclerosis, has completed, sponsored by Providence Health & Services.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
To date, there are no published data on the role of melatonin supplementation or the appropriate dose for patients with multiple sclerosis. Because of the potential benefits of melatonin, this pilot study will be an exploratory investigation to evaluate the effect of supplementing melatonin in subjects with multiple sclerosis who are taking an oral disease modifying therapy (DMT) for 6 months or longer. It is our intent that the results of this study will support the rationale and be a prelude to a larger trial which can focus on clinical efficacy of melatonin therapy outcomes.
Conditions Studied
Interventions
- DRUG 3 mg Melatonin
- DRUG 5 mg Melatonin
Study Locations (1)
Oregon
- Providence MS Center - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2018-05-09 |
| Est. Completion | 2023-12-11 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03498131
The ClinicalTrials.gov registry entry for NCT03498131 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 201-participant average among 25 other Relapsing Remitting Multiple Sclerosis trials with a reported enrollment target (85% lower). The listed sponsor is Providence Health & Services, which has 69 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsing Remitting Multiple Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which 3 mg Melatonin is the first listed.
NCT03498131 reports 1 study location spanning 1 distinct geographic area - top geographies include Oregon.
Frequently Asked Questions
What is clinical trial NCT03498131 about?
NCT03498131 is a clinical study titled "Melatonin in Patients With Multiple Sclerosis (MS).". To date, there are no published data on the role of melatonin supplementation or the appropriate dose for patients with multiple sclerosis. Because of the potential benefits of melatonin, this pilot study will be an exploratory investigation to evaluate the effect of supplementing melatonin in subje...
What is the current status of trial NCT03498131?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2018-05-09. Estimated completion is 2023-12-11.
What conditions does trial NCT03498131 study?
This clinical trial studies the following conditions: Relapsing Remitting Multiple Sclerosis.
What interventions are being tested in trial NCT03498131?
The interventions under investigation include: 3 mg Melatonin (DRUG), 5 mg Melatonin (DRUG).
Who is sponsoring clinical trial NCT03498131?
This trial is sponsored by Providence Health & Services, which has 69 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03498131 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsing Remitting Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Exploratory Study on the Timing of Multiple Sclerosis (MS) Symptoms
RECRUITING
-
Study to Evaluate the Usability and Value of Integrated Digital Solutions in Medical Care of Participants With Multiple Sclerosis
RECRUITING
-
The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study
RECRUITING · NA
-
Functional Outcomes From Diets in Multiple Sclerosis
RECRUITING · NA
-
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
RECRUITING · Phase 3
-
Clinically Isolated Syndrome and Relapsing-Remitting Multiple Sclerosis
ACTIVE NOT RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.